
W. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer.

W. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer.







Treating AML With Myelodysplasia-Related Changes








Treatment Options and Care for Patients Who Develop Therapy-Related AML

Martin Hutchings, MD, PhD, senior consultant in the Department of Hematology at the Copenhagen University Hospital, discusses common implications in treating patients with advanced stage Hodgkin lymphoma. Trials rarely perform subgroup analyses, and when they do, it is common for researchers to come across particular biases in the selected subgroups.








Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer




A 50-Year-Old Woman With ALK-Rearranged NSCLC

Robert "Bo" Gamble, director of strategic practice initiatives at Community Oncology Alliance, shares his perspective on the 340B Drug Discount Program and the implications of the program for the oncology community. He also provides his thoughts on possible solutions for imbalances created by the program.